A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01350947 |
Recruitment Status :
Completed
First Posted : May 10, 2011
Results First Posted : October 29, 2015
Last Update Posted : June 13, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The primary objective of this study is:
Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2. The primary objective is:
To determine the rate of complete hematologic response and hematologic improvement (according to IWG 2006 criteria) in CMML patients treated with 5-azacitidine.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Myelomonocytic Leukemia | Drug: 5-Azacitidine | Phase 2 |
In this study, eligible patients with a confirmed diagnosis of CMML will be treated with 5-azacitidine to determine the rates of complete hematologic response, hematologic improvement, complete and partial cytogenetic response, and overall and progression free survival.
To develop biomarkers associated with response and gain insights into the mechanisms that determine response, gene expression profiling, genome-wide SNP array analysis, microRNA analysis, and DNA methylation analysis will be performed prior to therapy and at defined time points during the study. Phosphoproteomics profiling may be included in the analysis.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML) |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | September 2014 |
Actual Study Completion Date : | September 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: All patients
All participants enrolled.
|
Drug: 5-Azacitidine
Administered on Days 1-7 of each Cycle. Subcutaneous administration: To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration. The 5-azacitidine suspension is administered subcutaneously. Intravenous Administration: 5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes. Other Name: Vidaza® |
- Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine. [ Time Frame: 24 months ]Complete Hematologic Response is defined as: bone marrow evaluation shows <= 5% myeloblasts with normal maturation of all cells lines; peripheral blood evaluation shows hemoglobin >= 11 g/dL, neutrophils >= 1000/mL, platelets >= 100,000/mL, 0% blasts

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis of CMML as defined by the WHO criteria
- Persistent peripheral blood monocytosis of more than 1 x 109/L for at least 3 months and
- No Philadelphia chromosome or BCR-ABL fusion gene and
- Less than 20% blasts in the blood or bone marrow and
- Dysplasia in one or more of the myeloid lineages* * In the absence of dysplasia in one or more of the myeloid lineages, the diagnosis of CMML can still be made if a) - c) are met AND an acquired clonal chromosomal abnormality is present in the bone marrow cells, the monocytosis has been present for more than 3months AND all other causes of monocytosis have been ruled out.
- Age of 18 years or older. Both men and women and members of all races and ethnic groups will be included.
- ECOG performance status <3
-
Adequate organ function defined as:
- Total bilirubin <2.5 x upper limit of normal (ULN)
- Direct bilirubin <2 x ULN
- Creatinine <2 mg/dL
- ALT and AST <2.5 x ULN
- Ability to understand and the willingness to sign a written informed consent document
- Willingness to use adequate contraception for the duration of the study
Exclusion Criteria:
- Progression to acute myeloid leukemia (defined by at least 20% blasts in the blood or bone marrow). In the unlikely event that progression to acute leukemia is demonstrated in the "screening" bone marrow biopsy, it is at the discretion of the investigator to enroll the patient after adequate discussion of the findings and alternative therapies. Enrollment of such a patient must be reported to the HCI PI.
- Presence of activating mutations of the platelet derived growth factor receptors alpha or beta, which would suggest likely benefit from imatinib treatment (these mutations will usually be obvious from karyotyping and fluorescence in situ hybridization studies)
- Known or suspected hypersensitivity to 5-azacitidine or mannitol
- Clinically significant heart disease (New York Heart Association Class III or IV) or other serious intercurrent illnesses or psychiatric illness/social situations that would limit compliance with study requirements
- Major surgery within 28 days before registration (exception: central venous line placement), or lack of full recovery from prior major surgery
- Prior therapy with a hypomethylating agent
- Cytotoxic chemotherapy less than 2 weeks prior to starting study medication (exception: hydroxyurea and/or anagrelide)
- Erythropoietin or darbepoietin, G-CSF, GM-CSF, thalidomide or lenalidomide less than 2 weeks from day 1 of cycle 1
- Concomitant cytotoxic chemotherapy (exception: hydroxyurea for up to 1 week per cycle)
- Concomitant therapy with other investigational agents
- Other active malignancies except basal cell carcinoma of the skin and carcinoma in situ of the cervix.
- Pregnancy or breastfeeding (possible risk to the fetus or infant)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01350947
United States, New York | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14263 | |
United States, Oregon | |
Oregon Health and Science University | |
Portland, Oregon, United States, 97239 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84112 |
Principal Investigator: | Michael Deininger, MD | University of Utah |
Responsible Party: | University of Utah |
ClinicalTrials.gov Identifier: | NCT01350947 |
Other Study ID Numbers: |
HCI47081 |
First Posted: | May 10, 2011 Key Record Dates |
Results First Posted: | October 29, 2015 |
Last Update Posted: | June 13, 2016 |
Last Verified: | May 2016 |
Chronic Myelomonocytic Leukemia CMML |
Leukemia Leukemia, Myelomonocytic, Acute Leukemia, Myelomonocytic, Chronic Leukemia, Myelomonocytic, Juvenile Neoplasms by Histologic Type Neoplasms Leukemia, Myeloid Myelodysplastic-Myeloproliferative Diseases |
Bone Marrow Diseases Hematologic Diseases Azacitidine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |